Alexion’s rare disease drug Soliris has been approved in a new use in Europe, to tackle a disorder of the optic nerves for which it recently got FDA approval.
NHS England has agreed to reimburse Roche’s Hemlibra (emicizumab) in a new group of patients with haemophilia A, widening access to the potentially life-saving drug.
Scotland’s cost-effectiveness body has rejected regular NHS funding for Vertex’s cystic fibrosis drugs Orkambi and Symkevi because of concerns about whether their high costs justify uncerta
Regeneron has announced data that could create a niche for its latest cholesterol drug evinacumab in a small group of patients who do not respond to the strongest available medicines.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
